IVEVF - Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches
Introduction
It is remarkable how few articles have been published about Genfit (GNFT) lately on Seeking Alpha. The last articles dated from June and August last year. This is quite remarkable since the company is nearing its make-or-break moment and indicates that investors’ confidence is at a low point. Before the end of Q2 the company will have released topline interim phase III results on its lead product (Elafibranor) in its lead indication ((NASH)). If proven effective, this milestone suffices to get FDA and EMA approval through an accelerated approval process. Less remarkable is